Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemoradiotherapy in Locally Advanced Gastric/GEJ Cancer
NCT05687357Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Pathological Complete Response Rate at 22 weeks. Started Mar 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05687357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687357.